346 related articles for article (PubMed ID: 15705272)
21. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.
Piroth L; Carrat F; Larrat S; Goderel I; Martha B; Payan C; Lunel-Fabiani F; Bani-Sadr F; Perronne C; Cacoub P; Pol S; Morand P
J Hepatol; 2008 Dec; 49(6):892-8. PubMed ID: 18752863
[TBL] [Abstract][Full Text] [Related]
23. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.
Hung CC; Hsiao CF; Wang JL; Chen MY; Hsieh SM; Sheng WH; Chang SC
Int J STD AIDS; 2005 Oct; 16(10):673-6. PubMed ID: 16212714
[TBL] [Abstract][Full Text] [Related]
24. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.
Reiche EM; Bonametti AM; Morimoto HK; Morimoto AA; Wiechemann SL; Matsuo T; Vissoci Reiche F; Vogler IH
Int J Mol Med; 2008 Mar; 21(3):387-95. PubMed ID: 18288387
[TBL] [Abstract][Full Text] [Related]
25. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria.
lsa SE; Gwamzhi LN; Akolo C; Giyan J
Niger J Med; 2010; 19(3):279-85. PubMed ID: 20845631
[TBL] [Abstract][Full Text] [Related]
26. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
[TBL] [Abstract][Full Text] [Related]
27. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.
Lincoln D; Petoumenos K; Dore GJ;
HIV Med; 2003 Jul; 4(3):241-9. PubMed ID: 12859323
[TBL] [Abstract][Full Text] [Related]
28. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V; Kallan MJ; Tate JP; Localio AR; Lim JK; Goetz MB; Klein MB; Rimland D; Rodriguez-Barradas MC; Butt AA; Gibert CL; Brown ST; Park L; Dubrow R; Reddy KR; Kostman JR; Strom BL; Justice AC
Ann Intern Med; 2014 Mar; 160(6):369-79. PubMed ID: 24723077
[TBL] [Abstract][Full Text] [Related]
29. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
[TBL] [Abstract][Full Text] [Related]
31. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
[TBL] [Abstract][Full Text] [Related]
32. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
33. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.
Martel-Laferrière V; Nitulescu R; Cox J; Cooper C; Tyndall M; Rouleau D; Walmsley S; Wong L; Klein MB;
BMC Infect Dis; 2017 Jan; 17(1):80. PubMed ID: 28095797
[TBL] [Abstract][Full Text] [Related]
34. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
36. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
[TBL] [Abstract][Full Text] [Related]
37. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
Petoumenos K; Ringland C;
HIV Med; 2005 May; 6(3):155-63. PubMed ID: 15876281
[TBL] [Abstract][Full Text] [Related]
39. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
